Eckel, MD, professor of medicine, emeritus in the division of endocrinology, metabolism and diabetes ... of semaglutide (Wegovy, Novo Nordisk) on cardiovascular outcomes for adults with obesity ...

For overweight or obese individuals without diabetes ... data from the SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity, which showed the cardiac ...

In a large clinical trial, researchers found that semaglutide ... proven to lower this cardiovascular risk is a major advance for public health,” John Sharretts, M.D., director of the division of ...

In the logistic regression model of the top 20 factors, significant associations for semaglutide initiation included being female (adjusted odds ratio, 2.30), using certain medication classes ...

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing significant insurance coverage disparities.

Female sex, antidepressant use, and type of health insurance significantly influence semaglutide initiation. (HealthDay News) — Sociodemographic, health care, and clinical factors are associated ...

Good response to obesity treatment or achieving ... to compare the prevalence of cardiovascular outcomes, like type 2 diabetes, hypertension and dyslipidemia in adulthood. The researchers followed ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

Semaglutide (known ... since the prevalence of obesity in people with type 1 diabetes is increasing and is associated with the risk of cardiovascular disease and complications.